Redeye comments on Cantargia’s license deal with Otsaka Pharmaceutical, which is transformative for the company since it means both CAN10 (the deal's target) and nadunolimab (the main candidate) are now funded.
ANNONS
Redeye comments on Cantargia’s license deal with Otsaka Pharmaceutical, which is transformative for the company since it means both CAN10 (the deal's target) and nadunolimab (the main candidate) are now funded.
